

## IRB Chair Letter

### IRB Chair Letter

Check here to enter IRB Chair LetterComment:  
MEMORANDUM

Department of Health and Human Services

Food and Drug Administration  
Research Involving Human Subjects Committee

---

DATE: May 4, 2017  
FROM: Chair, Research Involving Human Subjects Committee  
SUBJECT: RIHSC Protocol #17-032CTP  
Study Title: "Experimental Study on Warning Statements for Cigarette Graphic Health Warnings"

Principal Investigator: James M. Nonnemaker, PhD, MSPH, BS; RTI International  
FDA Sponsor: David B. Portnoy, PhD, MPH; CTP  
TO: David B. Portnoy, PhD, MPH; CTP  
Cathy Backinger, PhD, MPH; CTP Liaison to the RIHSC

You have submitted a request for RIHSC review for your proposal entitled, "Experimental Study on Warning Statements for Cigarette Graphic Health Warnings." Your study proposes to examine consumer reactions to two different versions of textual warning statements that focus on negative health consequences of cigarette use. The study aims to compare the effect of exposure to the 9 original statements in the Tobacco Control Act to revised versions of those statements. Because your protocol is no greater than minimal risk, it could be reviewed using the expedited procedure outlined in 45 CFR 46.110.

The RIHSC determined your study satisfies the criteria outlined in 45 CFR 46.404 for research not involving greater than minimal risk to children. Assent and parental permission will be obtained prior to the start of the study.

Your study proposal is APPROVED.

EFFECTIVE PERIOD OF APPROVAL:

This study has been approved May 4, 2017 to May 3, 2018.

FDA IRB:

Research Involving Human Subjects Committee, FWA #00006196

Chair: Jeffrey DeGrasse, PhD

Office of the Commissioner

Food and Drug Administration

RESPONSIBILITIES:

The Principal Investigator is responsible for ensuring that the investigation is conducted according to the investigational plan and applicable regulations and for protecting the rights, safety, and welfare of subjects. The Principal Investigator is also responsible for complying with the following requirements:

1. Promptly reporting to the RIHSC all changes in the research activity including any modifications to the Study Protocol or Informed Consent. 45 CFR 46.103(b)(4)(iii) Changes in approved research may not be initiated without RIHSC review and approval except when necessary to eliminate apparent immediate hazards to the subjects. 45 CFR 46.103(b)(4)(iii)
2. Promptly reporting to the RIHSC all unanticipated problems involving risk to human subjects or others. 45 CFR 46.103(b)(5)(i)
3. Providing periodic reports to the RIHSC, as required. 45 CFR 46.109(e)

PROGRESS OR FINAL REPORT:

If you wish to continue your study beyond May 3, 2018, you will need to submit a continuing review application and all supporting documentation to the RIHSC no later than March 21, 2018. If your study is completed or terminated within the next year, please submit a FINAL REPORT to the RIHSC Executive Director. This report should contain the following information, if applicable:

1. RIHSC FILE Number/Study Title/Study Investigator(s)/Institution where study is being/was conducted.
2. Brief summary of the project status, including a description of all changes, amendments, or supplements to the previously approved protocol and consent form.
3. Number of subjects initially approved by the RIHSC for inclusion in the study and the number actually entered into the study.
4. Number of subjects whose participation was completed as planned.
5. Number of subjects that dropped out of the study.
6. Summary of Adverse Events that can reasonably be attributed to the study.
7. List of abstracts or publications, and/or a brief description of any available study results.

If you have questions, or would like further information, please do not hesitate to contact the RIHSC Program Management Staff by email at RIHSC@fda.hhs.gov, or by phone at (301) 796-9605.

Signed By:



---

IRB Chair